Antares Pharma, Inc. (NASDAQ:ATRS)

CAPS Rating: 3 out of 5

The Company develops, produces and markets pharmaceutical delivery products, including transdermal gels, oral fast melting tablets and reusable needle-free and disposable mini-needle injector systems.


Player Avatar Shadowplay1 (< 20) Submitted: 12/6/2012 3:24:14 PM : Outperform Start Price: $3.83 ATRS Score: -78.07

Antares is gearing up for what I think will be a block bluster of a drug and that is Vibex MTX. Management has already said they plan to file an NDA with the FDA in Q1 of 2013 and when they do the stock should take off in anticipation of an early release from the FDA. Management has already done their own private studies with MTX and had an astonishing 96% approval rating. At a little under $4 a share, I think this could really benefit someones portfolio for the next two to three years.

Featured Broker Partners